Genetic Technologies (ASX:GTG) has completed the acquisition of the direct-to-consumer eCommerce business and distribution rights associated with AffinityDNA.
The company announced the planned acquisition on 16 May 16 saying it provides an additional platform for growth in the consumer genomics market through leveraging AffinityDNA’s well-established marketplace worldwide, including in the US, UK, and Europe.
The company said the acquisition expands GTG’s portfolio of tests to 51 tests in 14 categories across more than 40 countries.
GTG CEO Simon Morriss said, “AffinityDNA is an exciting addition to the GTG Group. This acquisition builds on our direct-to-consumer sales channel and supports the promotion of the geneType Multi Risk test for serious disease across our target markets worldwide.
"We are looking forward to working closely with the AffinityDNA team to grow its already impressive sales performance.”